Effectiveness and safety of anlotinib in patients with advanced gynecological cancer: A multi-center real-world study (1253)

Anlotinib is a novel oral small-molecule multi-target tyrosine kinase inhibitor that has been approved to treat non-small cell lung cancer. However, its effectiveness and safety among patients with advanced gynecologic cancer have not been fully investigated. We conducted this study to address this issue in a real-world setting.